Archive for the ‘Shareholder’ Category
Emergent BioSolutions to Acquire Trubion Pharmaceuticals
Trubion provides promising clinical-stage therapeutic candidates in the targeted disease areas of oncology and autoimmunity
Trubion offers novel, protein therapeutic platforms and scientific expertise for developing innovative therapeutic candidates
Transaction leverages large pharma partnerships to provide sales and marketing infrastructureidates
Emergent reaffirms 2010 guidance for revenues and net income
ROCKVILLE, Md., Aug 12, 2010 (BUSINESS WIRE) –
Emergent BioSolutions Inc. [...]
In: Chief Executive Officer, Emergent Bioslutions, Fuad El-Hibri, Shareholder, Trubion Pharmaceuticals, United States · Tagged with: Biosolutions, Board of directors, Common stock, Emergent BioSolutions, Seattle, Stock, Systemic Lupus Erythematosus, Trubion Pharmaceuticals
Emergent Revises Upward 2010 Financial Forecast
Company anticipates total revenues of $275 to $300 million and net income of $40 to $50 million
ROCKVILLE, MD, July 20, 2010 – Emergent BioSolutions Inc. (NYSE:EBS) announced today that it is revising upwards its 2010 annual guidance to now reflect anticipated total revenues of $275 to $300 million and net income of [...]
In: Biothrax, Chief Executive Officer, Emergent Bioslutions, Food and Drug Administration, Fuad El-Hibri, Shareholder · Tagged with: Anthrax vaccines, Biothrax, Emergent BioSolutions, Food and Drug Administration, Infectious disease, Strategic National Stockpile, United States, US government
Emergent BioSolutions Inc., Q2 2009 Earnings Call Transcript
Emergent BioSolutions Inc., (EBS)
Q2 2009 Earnings Call
August 6, 2009 5:00 pm ET
Executives
Robert G. Burrows – Vice President, Investor Relations
Fuad El-Hibri – Chairman of the Board, Chief Executive Officer
R. Don Elsey – Chief Financial Officer
Daniel J. Abdun-Nabi – President, Chief Operating Officer
W. James Jackson, Ph.D. – Senior Vice President and Chief Scientific Officer
Analysts
Eric Schmidt [...]
In: Chief Executive Officer, Emergent Bioslutions, Fuad, Fuad El-Hibri, Shareholder, United States · Tagged with: Chairman, Chief executive officer, Chief financial officer, Chief operating officer, finance, Investor relations, United States, Vice president
Emergent BioSolutions Inc. (EBS) CEO & Chairman, 10% Owner Fuad El-hibri sells 15,000 Shares
CEO & Chairman, 10% Owner of Emergent BioSolutions Inc. (EBS) Fuad El-hibri sells 15,000 shares of EBS on 08/11/2009 at an average price of $16.78 a share.
EMERGENT BIOSULUTIONS INC. is a leading biopharmaceutical company dedicated to one simple mission – to protect life. EBS develops manufactures and commercializes vaccines and therapeutics that assist the body\’s [...]
In: Chief Executive Officer, Emergent Bioslutions, Fuad, Fuad El-Hibri, Shareholder, United States, Washington D.C · Tagged with: Anthrax, Anthrax vaccines, Emergent BioSolutions, Health, Infectious disease, Public health, U.S. Food and Drug Administration, Vaccine